Edaravone Diminishes Free Radicals from Circulating Neutrophils in Patients with Ischemic Brain Attack
-
- Aizawa Hitoshi
- The First Department of Medicine, Asahikawa Medical College
-
- Makita Yoshihiro
- The First Department of Medicine, Asahikawa Medical College
-
- Sumitomo Kazuhiro
- The First Department of Medicine, Asahikawa Medical College
-
- Aburakawa Yoko
- The First Department of Medicine, Asahikawa Medical College
-
- Katayama Takayuki
- The First Department of Medicine, Asahikawa Medical College
-
- NakataniEnomoto Setsu
- The First Department of Medicine, Asahikawa Medical College
-
- Suzuki Yasuhiro
- The First Department of Medicine, Asahikawa Medical College
-
- Fujiwara Kazuhiko
- Department of Neurology, National Douhoku Hospital
-
- Enomoto Hiroyuki
- Department of Neurology, National Douhoku Hospital
-
- Kuroda Kenji
- Department of Neurology, National Douhoku Hospital
-
- Kimura Takashi
- Department of Neurology, National Douhoku Hospital
-
- Yahara Osamu
- Department of Neurology, National Douhoku Hospital
-
- Koyama Satoshi
- Asahikawa Rehabilitation Hospital
-
- Maruyama Junichi
- Asahikawa Rehabilitation Hospital
-
- Nakamura Masao
- Department of Chemistry, Asahikawa Medical College
-
- Hasebe Naoyuki
- The First Department of Medicine, Asahikawa Medical College
-
- Kikuchi Kenjiro
- The First Department of Medicine, Asahikawa Medical College
Search this article
Abstract
Objective: Treatment with a free radical scavenger could be a new option for ischemic brain attack, however, little is known about the alteration of oxidative stress markers induced by edaravone, a novel free radical scavenger, in human ischemic brain attack.<br> Methods: We investigated the effects of edaravone on the oxidative stress markers in patients with ischemic brain attack. Twentyone patients with ischemic brain attack and 19 controls were enrolled in this study. Blood samples were obtained just before and soon after the first administration of edaravone (30 mg) or ozagrel (40 mg). Intracellular reactive oxygen species of neutrophils were measured using 6carboxy2', 7'dichlorodihydrofluorescin diacetate and a fluorescenceactivated cell sorter. Superoxide from neutrophils, induced by phorbol myristate acetate (PMA), was determined by luminolamplified chemiluminescence assay.<br> Results: Treatment with 30 mg of edaravone significantly decreased the intracellular reactive oxygen species (ROS) of neutrophils (Wilcoxon test, p=0.0001) and PMAinduced superoxide produced by neutrophils (Wilcoxon test, p=0.001). Ozagrel did not alter the intracellular ROS or superoxide production of neutrophils.<br> Conclusion: Reduction of intracellular ROS and suppression of superoxide production in neutrophils provide a potential explanation for the clinical efficacy of edaravone in patients with ischemic brain attack.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 45 (1), 1-4, 2006
The Japanese Society of Internal Medicine
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204866540416
-
- NII Article ID
- 130000076292
-
- ISSN
- 13497235
- 09182918
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed